SMS Pharmaceuticals Ltd
SMS Pharmaceuticals Ltd (SMSPHARMA) last reported results for the quarter ended Jun 2026, with sales of ₹207 crore and net profit of ₹21 crore. The stock last traded at ₹475, a market capitalisation of ₹4,446 crore, on a P/E of 43.4. Over the past 52 weeks the stock has ranged between ₹262 and ₹494. Figures are as of 6 Oct 2026 and are not real time.
SMS Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹475
- Market cap
- ₹4,446 cr
- Stock P/E
- 43.4
- Book value
- ₹83.9
- ROE
- 14.3%
- ROCE
- 13.3%
- Dividend yield
- 0.08%
- 52w high / low
- 494/262
Metrics as of 6 Oct 2026. Not real time.
Track SMS Pharmaceuticals Ltd
Cruxal reads every SMS Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
SMS Pharmaceuticals Ltd growth and returns
- 10 Years
- 4%
- 5 Years
- 10%
- 3 Years
- 19%
- TTM
- 10%
- 10 Years
- 10%
- 5 Years
- 10%
- 3 Years
- 155%
- TTM
- 40%
- 10 Years
- 18%
- 5 Years
- 25%
- 3 Years
- 57%
- 1 Year
- 79%
- 10 Years
- 11%
- 5 Years
- 10%
- 3 Years
- 12%
- Last Year
- 14%
SMS Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹207 cr, up 5.6% from ₹196 cr a year earlier. Net profit was ₹21 cr, up 5.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 197 | 173 | 248 | 196 | 242 | 210 | 238 | 207 |
| Expenses | 165 | 140 | 207 | 157 | 194 | 167 | 198 | 166 |
| Operating profit | 31 | 33 | 41 | 39 | 48 | 44 | 40 | 41 |
| OPM % | 16% | 19% | 16% | 20% | 20% | 21% | 17% | 20% |
| Other income | 1 | 2 | 1 | 1 | 1 | 4 | 3 | 2 |
| Interest | 5 | 4 | 5 | 6 | 6 | 6 | 5 | 6 |
| Depreciation | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 |
| Profit before tax | 20 | 22 | 29 | 24 | 34 | 31 | 27 | 27 |
| Tax % | 29% | 24% | 30% | 23% | 26% | 26% | 23% | 26% |
| Net profit | 14 | 18 | 20 | 20 | 25 | 23 | 33 | 21 |
| EPS (₹) | 1.66 | 2.15 | 2.29 | 2.31 | 2.70 | 2.51 | 3.49 | 2.23 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
SMS Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 438 | 463 | 465 | 412 | 563 | 520 | 522 | 709 | 783 | 887 | 898 |
| Operating profit | 75 | 93 | 90 | 80 | 121 | 115 | 55 | 117 | 139 | 171 | 173 |
| OPM % | 17% | 20% | 19% | 19% | 22% | 22% | 10% | 16% | 18% | 19% | 19% |
| Net profit | 28 | 32 | 40 | 32 | 63 | 62 | -7 | 50 | 69 | 102 | 102 |
| EPS (₹) | 3.36 | 3.75 | 4.73 | 3.73 | 7.38 | 7.35 | -0.83 | 5.88 | 7.80 | 10.89 | 10.93 |
TTM is the trailing twelve months to the most recent quarter.
SMS Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Reserves | 246 | 276 | 313 | 340 | 402 | 462 | 452 | 528 | 631 | 776 |
| Borrowings | 149 | 146 | 144 | 157 | 255 | 263 | 254 | 281 | 311 | 365 |
| Other liabilities | 89 | 72 | 93 | 103 | 147 | 126 | 165 | 217 | 202 | 212 |
| Total liabilities | 493 | 503 | 559 | 608 | 812 | 860 | 880 | 1,034 | 1,153 | 1,362 |
| Fixed assets | 290 | 279 | 281 | 280 | 457 | 438 | 412 | 437 | 533 | 534 |
| CWIP | 8 | 8 | 18 | 42 | 7 | 11 | 33 | 30 | 35 | 122 |
| Investments | 29 | 28 | 27 | 26 | 27 | 22 | 11 | 11 | 12 | 26 |
| Other assets | 166 | 187 | 232 | 259 | 321 | 389 | 424 | 556 | 573 | 681 |
| Total assets | 493 | 503 | 559 | 608 | 812 | 860 | 880 | 1,034 | 1,153 | 1,362 |
As reported by the company. Total assets equal total liabilities by construction.
SMS Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 73 | 32 | 50 | 40 | 90 | 45 | 22 | 50 | 82 | 59 |
| Cash from investing | -39 | -17 | -35 | -43 | -152 | -27 | -30 | -52 | -123 | -131 |
| Cash from financing | -33 | -15 | -13 | -2 | 92 | -12 | -32 | 31 | 47 | 76 |
| Net cash flow | 1 | 0 | 2 | -5 | 31 | 6 | -39 | 29 | 5 | 4 |
| Free cash flow | 50 | 23 | 15 | -3 | -61 | 18 | -7 | -2 | -42 | -71 |
| CFO / operating profit | 110% | 46% | 70% | 65% | 88% | 52% | 50% | 56% | 73% | 49% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
SMS Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 13% | 18% | 17% | 13% | 17% | 13% | 4% | 12% | 13% | 13% |
| Debtor days | 18 | 19 | 20 | 43 | 68 | 34 | 104 | 122 | 95 | 89 |
| Inventory days | 114 | 135 | 170 | 191 | 148 | 333 | 243 | 201 | 238 | 260 |
| Days payable | 82 | 49 | 59 | 66 | 70 | 97 | 117 | 130 | 95 | 89 |
| Cash conversion cycle | 50 | 105 | 131 | 169 | 146 | 270 | 230 | 192 | 237 | 260 |
| Working capital days | -2 | 27 | 39 | 57 | 48 | 94 | 104 | 85 | 88 | 98 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
SMS Pharmaceuticals Ltd shareholding pattern
Promoters held 68.07% at Jun 2026, up from 66.27% at Jun 2025. FIIs 0.65% and DIIs 2.83%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 64.67% | 64.67% | 66.27% | 66.27% | 68.07% | 68.07% | 68.07% | 68.07% |
| FIIs | 0.52% | 0.31% | 0.08% | 0.03% | 0.28% | 0.04% | 0.31% | 0.65% |
| DIIs | 2.55% | 2.55% | 2.43% | 3.03% | 2.88% | 3.21% | 3.02% | 2.83% |
| Public | 32.27% | 32.47% | 31.23% | 30.68% | 28.77% | 28.69% | 28.60% | 28.45% |
| No. of shareholders | 33,136 | 34,973 | 35,332 | 33,652 | 34,157 | 34,378 | 32,397 | 31,489 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
SMS Pharmaceuticals Ltd corporate filings
- Certificate under Reg 74(5) of SEBI DP Regulations for quarter ended 30 September 2026Company Updatelow impact
- Corporate Voting Results of SMS Pharmaceuticals Limited's 38th AGM Indicate Broad Shareholder Support for Key ResolutionsAGM/EGMlow impact
Cruxal's analysis: SMS Pharmaceuticals Limited held its 38th AGM on 29th September 2026 via VC/OAVM, with…
Read the full analysis - Proceedings of the Annual General Meeting of the CompanyAGM/EGMmedium impact
- Trading window closure for the quarter and half year ended on 30 September 2026Insider Trading / SASTlow impact
- SMS Pharmaceuticals Ltd announces investor group meetingCompany Updatelow impact
Cruxal's analysis: SMS Pharmaceuticals Ltd has issued an intimation regarding an upcoming meeting with an…
Read the full analysis - SMS Pharmaceuticals Ltd: Disclosure of Newspaper Publication regarding routine corporate filingsCompany Updatelow impact
Cruxal's analysis: SMS Pharmaceuticals Ltd has published a notice in newspapers as part of its regulatory…
Read the full analysis - SMS Pharmaceuticals Ltd issues letter to shareholders regarding Annual ReportCompany Updatelow impact
Cruxal's analysis: SMS Pharmaceuticals has issued a formal letter to shareholders in conjunction with the…
Read the full analysis - SMS Pharmaceuticals Ltd files Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: SMS Pharmaceuticals has submitted its Business Responsibility and Sustainability Report…
Read the full analysis - SMS Pharmaceuticals Announces 38th AGM and FY 2025-26 Annual ReportAGM/EGMhigh impact
Cruxal's analysis: SMS Pharmaceuticals Limited has scheduled its 38th Annual General Meeting (AGM) for…
Read the full analysis - SMS Pharmaceuticals Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: SMS Pharmaceuticals has filed its Annual Report for the financial year 2025-26. The…
Read the full analysis - SMS Pharmaceuticals Limited: CARE Ratings Reaffirms 'CARE A' Rating with Outlook Revised from Positive to StableCompany Updatemedium impact
Cruxal's analysis: SMS Pharmaceuticals Limited has received a credit rating update from CARE Ratings, which…
Read the full analysis - SMS Pharmaceuticals Ltd: Routine Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: SMS Pharmaceuticals has published the mandatory newspaper advertisement regarding its…
Read the full analysis - SMS Pharmaceuticals Limited announces revised schedule for 38th Annual General Meeting and Dividend Record DateAGM/EGMlow impact
Cruxal's analysis: SMS Pharmaceuticals Limited has rescheduled its 38th Annual General Meeting to 29th…
Read the full analysis - SMS Pharmaceuticals Ltd announces 38th Annual General Meeting via VC/OAVMCompany Updatelow impact
Cruxal's analysis: SMS Pharmaceuticals Ltd has published a newspaper notice regarding its 38th Annual…
Read the full analysis - SMS Pharmaceuticals Limited issues dividend tax deduction communication for FY 2025-26Company Updatelow impact
Cruxal's analysis: SMS Pharmaceuticals Limited has issued a routine communication to shareholders regarding…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.